

Federico Cappuzzo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5408729/federico-cappuzzo-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

266
papers

28,768
citations

66
h-index

168
g-index

304
ext. papers

33,369
ext. citations

5.6
avg, IF

6.47
L-index

#	Paper	IF	Citations
266	MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. <i>Science</i> , 2007 , 316, 1039-43	33.3	3705
265	First-line crizotinib versus chemotherapy in ALK-positive lung cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 2167-77	59.2	2116
264	Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. <i>New England Journal of Medicine</i> , 2018 , 378, 2288-2301	59.2	1695
263	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. <i>Lancet Oncology</i> , 2010 , 11, 753-62	21.7	1653
262	Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 643-55	9.7	1367
261	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. <i>Lancet Oncology</i> , 2015 , 16, 257-65	21.7	1050
260	Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , 2010 , 11, 521-9	21.7	982
259	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. <i>Nature Genetics</i> , 2012 , 44, 1104-10	36.3	919
258	Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. <i>Lancet</i> , 2014 , 384, 665-73	40	799
257	Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. <i>Science Translational Medicine</i> , 2010 , 2, 62ra93	17.5	646
256	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 924-937	21.7	562
255	Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. <i>Science Translational Medicine</i> , 2011 , 3, 99ra86	17.5	463
254	Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1667-74	2.2	456
253	PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. <i>British Journal of Cancer</i> , 2015 , 112, 95-102	8.7	407
252	Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 387-401	35.1	398
251	Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5007-18	2.2	333
250	Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 1133-41	9.7	333

249	Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 4570-9	12.9	326
248	Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. <i>Annals of Oncology</i> , 2004 , 15, 1042-7	10.3	281
247	Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. <i>Journal of Clinical Oncology</i> , 2015 , 33, 992-9	2.2	266
246	Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4113-20	2.2	244
245	MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2009 , 20, 298-304	10.3	243
244	Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1706-13	8.9	237
243	Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. <i>Annals of Oncology</i> , 2007 , 18, 752-60	10.3	232
242	EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. <i>Annals of Oncology</i> , 2008 , 19, 717-23	10.3	225
241	Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3279-87	2.2	223
240	Role of gemcitabine in cancer therapy. <i>Future Oncology</i> , 2005 , 1, 7-17	3.6	213
239	Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. <i>Oncogene</i> , 2009 , 28 Suppl 1, S32-7	9.2	202
238	Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2248-55	2.2	198
237	Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2251-2258	2.2	197
236	Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2658-63	2.2	192
235	Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4253-60	2.2	191
234	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. <i>Annals of Oncology</i> , 2016 , 27, 281-6	10.3	187
233	Targeting MET in Lung Cancer: Will Expectations Finally Be MET?. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 15-26	8.9	186
232	HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2006 , 354, 2619-21	59.2	183

231	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. <i>Nature Communications</i> , 2014 , 5, 3518	17.4	173
230	Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2858-65	2.2	171
229	Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1351-1360	8.0	160
228	Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. <i>British Journal of Cancer</i> , 2008 , 99, 83-9	8.7	155
227	Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial. <i>Lung Cancer</i> , 2008 , 59, 355-63	5.9	137
226	IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, LBA9000-LBA9000	2.2	136
225	Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. <i>Annals of Oncology</i> , 2009 , 20, 1674-81	10.3	134
224	Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4789-95	2.2	134
223	Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. <i>Journal of Clinical Oncology</i> , 1996 , 14, 2546-51	2.2	117
222	HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2013 , 108, 668-75	8.7	109
221	Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2003 , 41, 227-31	5.9	105
220	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. <i>Journal of Thoracic Oncology</i> , 2006 , 1, S13-S19	8.9	100
219	Epidermal growth factor receptor inhibition in lung cancer: status 2012. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 373-84	8.9	99
218	EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. <i>Cancer Treatment Reviews</i> , 2012 , 38, 416-30	14.4	97
217	EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. <i>Journal of Clinical Pathology</i> , 2009 , 62, 970-7	3.9	94
216	Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. <i>British Journal of Cancer</i> , 2008 , 99, 51-6	8.7	93
215	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. <i>Lung Cancer</i> , 2011 , 71, 249-57	5.9	92
214	Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2016 , 27, 1291-8	10.3	91

213	Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. <i>British Journal of Cancer</i> , 2012 , 107, 793-9	8.7	90
212	Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 3078-84	12.9	85
211	Crizotinib in -Deregulated or -Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 7312-7319	12.9	80
210	Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. <i>Cancer</i> , 2008 , 112, 1555-61	6.4	77
209	Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2019 , 129, 35-40	5.9	77
208	Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5620-6	2.2	76
207	Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. <i>Annals of Oncology</i> , 2012 , 23, 388-94	10.3	76
206	Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. <i>Neoplasia</i> , 2009 , 11, 1084-92	6.4	76
205	Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. <i>Annals of Oncology</i> , 2006 , 17, 1120-7	10.3	75
204	ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. <i>Archives of Pathology and Laboratory Medicine</i> , 2014 , 118, 1419-50	5	73
203	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program 2019 , 7, 99		71
202	HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. <i>British Journal of Cancer</i> , 2005 , 93, 1334-40	8.7	70
201	EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2007 , 2, 423-9	8.9	68
200	Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. <i>Oncotarget</i> , 2017 , 8, 13611-13619	3.3	66
199	Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. <i>European Journal of Cancer</i> , 2018 , 100, 126-134	7.5	65
198	Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. <i>British Journal of Cancer</i> , 2004 , 90, 31-5	8.7	65
197	Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. <i>Annals of Oncology</i> , 2010 , 21, 562-567	10.3	64
196	Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 545-555	8.9	63

195	Glutamine supplementation in cancer patients receiving chemotherapy: a double-blind randomized study. <i>Nutrition</i> , 1997 , 13, 748-51	4.8	62
194	microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 14924-9	11.5	61
193	Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9002-9002	2.2	59
192	Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study. <i>Lung Cancer</i> , 2013 , 82, 231-7	5.9	58
191	Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. <i>Oncologist</i> , 2010 , 15, 1102-12	5.7	56
190	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 2019 , 7, 316		56
189	Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. <i>BJU International</i> , 2013 , 111, 44-52	5.6	55
188	Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. <i>Drugs</i> , 2012 , 72 Suppl 1, 28-36	12.1	54
187	Primary pulmonary meningioma: report of a case and review of the literature. <i>Lung Cancer</i> , 2008 , 62, 401-7	5.9	51
186	Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2014 , 15, 173-81	4.9	50
185	HER2 and lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 1219-28	3.5	50
184	Assessment of tumor response in malignant pleural mesothelioma. <i>Cancer Treatment Reviews</i> , 2007 , 33, 533-41	14.4	50
183	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , 2019 , 123, 98-105	5.6	48
182	Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features. <i>International Journal of Oncology</i> , 2013 , 43, 765-74	4.4	48
181	Clinical implications of MET gene copy number in lung cancer. <i>Future Oncology</i> , 2010 , 6, 239-47	3.6	47
180	Clinical experience with gefitinib: an update. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 58, 31-45	7	46
179	Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). <i>British Journal of Cancer</i> , 2004 , 90, 82-6	8.7	46
178	Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. <i>Oncologist</i> , 2007 , 12, 211-20	5.7	43

177	MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies. <i>Clinical Colorectal Cancer</i> , 2014 , 13, 37-45.e4	3.8	41
176	MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 472-8	8.9	41
175	ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. <i>British Journal of Cancer</i> , 2003 , 89, 246-7	8.7	40
174	Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. <i>British Journal of Cancer</i> , 2019 , 120, 57-62	8.7	40
173	EGFR FISH versus mutation: different tests, different end-points. <i>Lung Cancer</i> , 2008 , 60, 160-5	5.9	39
172	Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , 1995 , 13, 2613-9	2.2	39
171	Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment. <i>Cancer Cytopathology</i> , 2014 , 122, 445-53	3.9	38
170	Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2012 , 23, 670-677	10.3	38
169	Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). <i>Reviews on Recent Clinical Trials</i> , 2006 , 1, 1-13	1.2	38
168	cMET Exon 14 Skipping: From the Structure to the Clinic. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1423-328.9		38
167	Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study. <i>Cancer</i> , 2003 , 98, 128-34	6.4	37
166	IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1909-1924	8.9	37
165	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. <i>Journal of Thoracic Oncology</i> , 2006 , 1, S13-S19	8.9	36
164	Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 6006-12	12.9	36
163	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. <i>Lung Cancer</i> , 2011 , 72, 3-8	5.9	35
162	Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 395-6	8.9	35
161	Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. <i>Lung Cancer</i> , 2016 , 93, 95-103	5.9	34
160	ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). <i>Clinical Lung Cancer</i> , 2020 , 21, 15-20	4.9	34

159	Targeted therapy for NSCLC with driver mutations. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 1401-1424	3.4	33
158	Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus. <i>Lung Cancer</i> , 2015 , 87, 89-95	5.9	33
157	Blockage of interleukin-1 β with canakinumab in patients with Covid-19. <i>Scientific Reports</i> , 2020 , 10, 21775-21784	4.9	33
156	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 . <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 2209-2221	7.4	32
155	Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Translational Lung Cancer Research</i> , 2017 , 6, 373-386	4.4	32
154	HER2 in solid tumors: more than 10 years under the microscope; where are we now?. <i>Future Oncology</i> , 2014 , 10, 1469-86	3.6	31
153	Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006 , 95, 45-53	4.4	30
152	First-line crizotinib versus pemetrexed \pm platin or pemetrexed \pm carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). <i>Journal of Clinical Oncology</i> , 2014 , 32, 8002-8002	2.2	30
151	Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1547-1558	8.0	30
150	Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. <i>Journal of Thoracic Oncology</i> , 2006 , 1, S13-9	8.9	30
149	The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients. <i>Translational Lung Cancer Research</i> , 2019 , 8, 429-449	4.4	29
148	cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance. <i>Cancers</i> , 2015 , 7, 556-73	6.6	29
147	Targeting c-MET in the battle against advanced nonsmall-cell lung cancer. <i>Current Opinion in Oncology</i> , 2013 , 25, 130-6	4.2	29
146	Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. <i>Journal of Clinical Pathology</i> , 2012 , 65, 218-23	3.9	29
145	The neuropilin 2 isoform NRP2b uniquely supports TGF β -mediated progression in lung cancer. <i>Science Signaling</i> , 2017 , 10,	8.8	28
144	Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. <i>Clinical Lung Cancer</i> , 2014 , 15, 411-417.e4	4.9	28
143	Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. <i>Lung Cancer</i> , 2017 , 112, 181-187	5.9	28
142	A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. <i>Lung Cancer</i> , 2006 , 52, 319-25	5.9	28

141	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020 , 21, 498-508.e2	4.9	27
140	The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC. <i>Journal of Clinical Pathology</i> , 2012 , 65, 1-7	3.9	27
139	Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. <i>Clinical Lung Cancer</i> , 2019 , 20, e186-e194	4.9	27
138	Strategies for improving outcomes in NSCLC: a look to the future. <i>Lung Cancer</i> , 2013 , 82, 375-82	5.9	26
137	Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer. <i>Biologics: Targets and Therapy</i> , 2013 , 7, 61-8	4.4	26
136	Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2005 , 93, 29-34	8.7	25
135	Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2016 , 99, 31-7	5.9	25
134	A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. <i>Journal of Thoracic Disease</i> , 2018 , 10, 3909-3921	2.6	24
133	Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. <i>Annals of Oncology</i> , 2006 , 17 Suppl 2, ii42-45	10.3	23
132	Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. <i>Oncologist</i> , 2019 , 24, e1165-e1171	5.7	23
131	Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 665-72	8.9	22
130	Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2016 , 8, 176-87	5.4	22
129	A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2014 , 25, 2156-2162	10.3	22
128	K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value 2012 , 2012, 837306		22
127	Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. <i>Lung Cancer</i> , 2012 , 76, 269-79	5.9	20
126	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019 , 133, 163-166	5.3	19
125	Experience with erlotinib in the treatment of non-small cell lung cancer. <i>Therapeutic Advances in Respiratory Disease</i> , 2015 , 9, 146-63	4.9	19
124	Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer. <i>Translational Respiratory Medicine</i> , 2014 , 2, 2		19

123	Emerging drugs for small cell lung cancer--an update. <i>Expert Opinion on Emerging Drugs</i> , 2012 , 17, 31-6	3.7	19
122	Irreversible EGFR-TKIs: dreaming perfection. <i>Translational Lung Cancer Research</i> , 2013 , 2, 40-9	4.4	19
121	Treating mutation resistance in non-small cell lung cancer - role of osimertinib. <i>The Application of Clinical Genetics</i> , 2017 , 10, 49-56	3.1	18
120	Emerging drugs for small-cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2009 , 14, 591-606	3.7	18
119	Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 1438-1447	21.7	18
118	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. <i>Gut</i> , 2015 , 64, 921-8	19.2	17
117	Rare mutations in non-small-cell lung cancer. <i>Future Oncology</i> , 2013 , 9, 699-711	3.6	17
116	IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	17
115	Protein kinase inhibitors to treat non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1203-13	4	16
114	Pharmacotherapy targeting the EGFR oncogene in NSCLC. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 2293-305	4	16
113	Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials. <i>Translational Lung Cancer Research</i> , 2015 , 4, 465-74	4.4	16
112	Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC). <i>Oncotarget</i> , 2018 , 9, 17554-17563	3.3	16
111	Erlotinib in the first-line treatment of non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 523-33	3.5	15
110	Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies. <i>Future Oncology</i> , 2018 , 14, 1477-1486	3.6	14
109	p95HER2 truncated form in resected non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 520-7	8.9	14
108	Impact of biomarkers on non-small cell lung cancer treatment. <i>Targeted Oncology</i> , 2010 , 5, 5-17	5	14
107	Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2003 , 42, 355-61	5.9	14
106	EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center. <i>Oncology Reports</i> , 2016 , 36, 1166-72	3.5	14

105	Management of NSCLC: focus on crizotinib. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 2587-97	4	13
104	Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. <i>Clinical Lung Cancer</i> , 2014 , 15, 470-479	4.9	12
103	Gemcitabine for the treatment of advanced nonsmall cell lung cancer. <i>OncoTargets and Therapy</i> , 2009 , 2, 209-17	4.4	12
102	Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer. <i>Annals of Oncology</i> , 2007 , 18 Suppl 9, ix150-5	10.3	12
101	Present and future treatment of advanced non-small cell lung cancer. <i>Seminars in Oncology</i> , 2002 , 29, 9-16	5.5	12
100	Gefitinib for non-small-cell lung cancer treatment. <i>Expert Opinion on Drug Safety</i> , 2011 , 10, 987-96	4.1	11
99	Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. <i>Cancers</i> , 2020 , 12,	6.6	11
98	Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?. <i>Drugs</i> , 2016 , 76, 831-40	12.1	11
97	Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study. <i>Lung Cancer</i> , 2015 , 90, 234-42	5.9	10
96	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019 , 135, 74-77	5.3	9
95	1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations. <i>Annals of Oncology</i> , 2020 , 31, S817-S818	10.3	9
94	Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 77-86	3.5	9
93	Prognostic Value of p16 Protein in Patients With Surgically Treated Non-small Cell Lung Cancer; Relationship With Ki-67 and PD-L1. <i>Anticancer Research</i> , 2020 , 40, 983-990	2.3	9
92	Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly. <i>Drugs and Aging</i> , 2015 , 32, 907-16	4.7	8
91	Emerging drugs for non-small cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2003 , 8, 179-92	3.7	8
90	Gemcitabine in non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2002 , 3, 745-53	4	8
89	The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target?. <i>Current Drug Targets</i> , 2014 , 15, 1284-92	3	8
88	Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. <i>Future Oncology</i> , 2020 , 16, 1433-1439	3.6	8

87	Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer. <i>Oncotarget</i> , 2019 , 10, 561-572	3.3	7
86	Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study. <i>PLoS ONE</i> , 2015 , 10, e0125037	3.7	7
85	1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations. <i>Annals of Oncology</i> , 2020 , 31, S837-S838	10.3	7
84	Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 1783-93	4.9	7
83	Targeting MET in NSCLC: looking for a needle in a haystack. <i>Translational Lung Cancer Research</i> , 2014 , 3, 389-91	4.4	7
82	Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. <i>Molecular Diagnosis and Therapy</i> , 2021 ,	4.5	7
81	A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens. <i>Cancer Cytopathology</i> , 2020 , 128, 928-938	3.9	7
80	Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). <i>Tumori</i> , 2019 , 105, 3-14	1.7	6
79	Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study. <i>Clinical Lung Cancer</i> , 2014 , 15, 338-45.e1	4.9	6
78	Predictive factors for response and for resistance to tyrosine kinase inhibitor therapy in lung cancer. <i>Journal of Thoracic Oncology</i> , 2007 , 2, S12-4	8.9	6
77	Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103176	7	6
76	KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 2065-2077	8.9	6
75	1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial. <i>Annals of Oncology</i> , 2020 , 31, S814-S815	10.3	5
74	Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients. <i>Expert Review of Respiratory Medicine</i> , 2020 , 14, 565-576	3.8	5
73	Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. <i>Radiotherapy and Oncology</i> , 2020 , 149, 84-88	5.3	5
72	Deregulation in Lung Cancer: Right Time to Adopt an Orphan?. <i>Clinical Cancer Research</i> , 2018 , 24, 2470-2473	4.7	5
71	Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 203-14	3.8	5
70	MET overexpression and gene amplification in NSCLC: a clinical perspective. <i>Lung Cancer: Targets and Therapy</i> , 2013 , 4, 15-25	2.9	5

69	C1-04: A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I). <i>Journal of Thoracic Oncology</i> , 2007 , 2, S359-S360	8.9	5
68	Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer. <i>Oncology</i> , 1995 , 52, 454-7	3.6	5
67	Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC. <i>Translational Lung Cancer Research</i> , 2016 , 5, 579-587	4.4	5
66	PS01.53: First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program. <i>Journal of Thoracic Oncology</i> , 2016 , 11, S302-S303	8.9	5
65	Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib. <i>Cancers</i> , 2019 , 11,	6.6	4
64	Consequences of targeted treatments for second-line therapy. <i>Annals of Oncology</i> , 2010 , 21 Suppl 7, vii234-40	10.3	4
63	New targeted therapies for non-small-cell lung cancer. <i>Therapy: Open Access in Clinical Medicine</i> , 2009 , 6, 335-350		4
62	Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. <i>ESMO Open</i> , 2016 , 1, e000118	6	4
61	Efficacy of crizotinib in ROS1-rearranged lung cancer: The European experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11035-11035	2.2	4
60	Impact of crizotinib on patient-reported general health status compared with chemotherapy in patients with no prior systemic treatment for advanced non-squamous ALK-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8101-8101	2.2	4
59	Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program. <i>Tumor Biology</i> , 2018 , 40, 1010428318815047	2.9	4
58	P3.02c-038 First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naïve Patients with Advanced NSCLC: A Phase III Clinical Program. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1296-S1297	8.9	3
57	Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: Results of the prospective PFROST trial. <i>Annals of Oncology</i> , 2019 , 30, v609-v610	10.3	3
56	First-Line Crizotinib Vs Pemetrexed + Cisplatin/Carboplatin in Asian Patients with Advanced Alk+ Nslc in Profile 1014. <i>Annals of Oncology</i> , 2014 , 25, v2	10.3	3
55	EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?. <i>Targeted Oncology</i> , 2008 , 3, 173-186	5	3
54	Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 461-2; author reply 462-3	9.7	3
53	Use of HER2 gene amplification to identify patients with metastatic colorectal cancer resistant to anti-EGFR monoclonal antibodies.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 474-474	2.2	3
52	Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2079-2079	2.2	3

51	COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience. <i>Breast Journal</i> , 2021 , 27, 359-362	1.2	3
50	Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
49	Minimizing Aircraft ECS Bleed Off-Take - Virtual Integrated Aircraft Applications. <i>SAE International Journal of Aerospace</i> , 2016 , 9, 151-162	0.3	3
48	P3.02c-095 Italian Nivolumab Expanded Access Programme: Efficacy and Safety Data in Squamous Non-Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1336-S1337	8.9	2
47	1900P RAMES trial: A multicentre, double-blind, randomized, phase II study on gemcitabine plus ramucirumab versus gemcitabine alone as second-line treatment for advanced malignant pleural mesothelioma (MPM). <i>Annals of Oncology</i> , 2020 , 31, S1078	10.3	2
46	First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly frail patients with advanced non-small-cell lung cancer: a multicenter phase II study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012 , 138, 2003-8	4.9	2
45	EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?. <i>Expert Opinion on Medical Diagnostics</i> , 2007 , 1, 183-91		2
44	Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?. <i>Journal of Thoracic Disease</i> , 2012 , 4, 226-8	2.6	2
43	How selecting best upfront therapy for metastatic disease?-Focus on ROS1-rearranged disease. <i>Translational Lung Cancer Research</i> , 2020 , 9, 2686-2695	4.4	2
42	Crizotinib in and Deregulated NSCLC-Response. <i>Clinical Cancer Research</i> , 2020 , 26, 1775	12.9	2
41	Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 80% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy.. <i>Thoracic Cancer</i> , 2021 ,	3.2	2
40	Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2014 , 5, 43-50	2.9	1
39	Is gemcitabine cost effective in cancer treatment?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007 , 7, 239-49	2.2	1
38	M03-02: Molecular predictors for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): role of egfr gene amplification. <i>Journal of Thoracic Oncology</i> , 2007 , 2, S156-S157	8.9	1
37	RESPONSE: Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 462-463	9.7	1
36	MET exon 14 mutations in advanced lung adenocarcinoma: Frequency and coexisting alterations.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20656-e20656	2.2	1
35	ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS9121-TPS9121	2.2	1
34	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting.. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211059873	5.4	1

33	Clinicopathologic correlates of pembrolizumab efficacy in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$		1
32	Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study. <i>Clinical and Translational Oncology</i> , 2020 , 22, 294-301	3.6	1
31	The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 669839	5.3	1
30	How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team. <i>Journal of Thoracic Disease</i> , 2018 , 10, 3883-3890	3.6	1
29	KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: "Survival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiously".. <i>Journal of Thoracic Oncology</i> , 2022 , 17, e40-e41	8.9	1
28	Role of Pembrolizumab in recurrent or metastatic head and neck carcinoma. <i>Oral Oncology</i> , 2021 , 115, 105133	4.4	0
27	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3713-3736	4.4	0
26	Chemoimmunotherapy for stage IV non-small-cell lung cancer - AuthorsReply. <i>Lancet Oncology, The</i> , 2019 , 20, e467	21.7	
25	Alectinib Resistance Through Amphiregulin Overexpression: Is Osimertinib the Best Candidate?. <i>Journal of Thoracic Oncology</i> , 2020 , 15, e92-e93	8.9	
24	The Role of ERBB Family Blockade in NSCLC. <i>The Journal of Oncopathology</i> , 2014 , 2, 51-58		
23	Anaplastic lymphoma kinase 1 detected by immunohistochemistry in non-small cell lung cancer: a promising feature?. <i>Human Pathology</i> , 2010 , 41, 614-5; author reply 615-616	3.7	
22	Optimizing Anti-EGFR Strategies in Cancer Treatment. <i>Current Cancer Therapy Reviews</i> , 2007 , 3, 267-275	0.4	
21	Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 1795; author reply 1795-6	9.7	
20	Multimodality therapy for non-small cell lung cancer (NSCLC): ongoing Italian experiences in the adjuvant and neoadjuvant settings. <i>Lung Cancer</i> , 2001 , 34 Suppl 3, S45-7	5.9	
19	Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer. <i>Annals of Translational Medicine</i> , 2015 , 3, 32	3.2	
18	EGFR TKIs as maintenance therapy in NSCLC: Finding the old in the new INFORMATION. <i>Translational Lung Cancer Research</i> , 2012 , 1, 160-2	4.4	
17	Lung Cancer Update 2017: from the test tube to the bed. <i>Annals of Translational Medicine</i> , 2018 , 6, 86	3.2	
16	The interplay between PD-L1 and vimentin in NSCLC patients: An exploratory analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20688-e20688	2.2	

- 15 Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC.. *Journal of Clinical Oncology*, **2014**, 32, 11056-11056 2.2
- 14 Resistance to anti-angiogenic drugs and therapeutic options **2015**, 61-66
- 13 Overcoming EGFR-TKI Resistance **2015**, 37-50
- 12 Resistance to EGFR TKIs **2015**, 27-36
- 11 Therapy options for advanced NSCLC **2015**, 5-25
- 10 Lung cancer patients with HER2 mutations treated with chemotherapy and HER2 targeted drugs: Results form the EUHER2 cohort study.. *Journal of Clinical Oncology*, **2015**, 33, 11076-11076 2.2
- 9 Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC.. *Journal of Clinical Oncology*, **2016**, 34, TPS9103-TPS9103 2.2
- 8 Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC: A phase IV study.. *Journal of Clinical Oncology*, **2017**, 35, e20676-e20676 2.2
- 7 MYC gene copy number (GCN) and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2012**, 30, e21018-e21018 2.2
- 6 Impact of IVS14+1G>A and 2846A>T DPYD polymorphisms on toxicity outcome of patients treated with fluoropyrimidine-containing regimens.. *Journal of Clinical Oncology*, **2013**, 31, 11058-11058 2.2
- 5 Micro-RNA signature differences in lung adenocarcinoma with specific driver alterations.. *Journal of Clinical Oncology*, **2013**, 31, 11066-11066 2.2
- 4 Predictive and Prognostic Implications of EGFR Mutations **2014**, 25-30
- 3 The Human Epidermal Growth Factor Receptor (HER) Family: Structure and Function **2014**, 7-17
- 2 EGFR-Targeted Therapies in Non-small Cell Lung Cancer **2014**, 31-66
- 1 Ceritinib for the treatment of non-small cell lung cancer. *Drugs of Today*, **2014**, 50, 465-73 2.5